Bispecific antibody · Immune activation, directed at prostate-specific membrane antigen (FOLH1) and CD28 · developed by REGENERON PHARMACEUTICALS
Nezastomig is a bispecific antibody that binds CD28 on cytotoxic T-lymphocytes and prostate-specific membrane antigen (PSMA) on tumor cells. By engaging both, it aims to activate and redirect T cells to PSMA-expressing cells. It is studied in metastatic castration-resistant prostate cancer and clear cell renal cell carcinoma.
Summary written with AI from the sources listed at the end of this page.
Clear Cell Renal Cell Carcinoma (ccRCC)Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Updated Nov 8, 2026. Something wrong or missing? Report it on the REGN page.
See REGN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
REGN catalysts and pipeline →